Dr Brian Kennedy on Rejuvant, human longevity trials, aging optimally and why individual response to intervention is key.
Alpha-ketoglutarate (AKG) is used by cells during growth and in healing from injuries; studies have shown it may be effective in treating osteoporosis, preventing a decline in protein synthesis, reducing frailty and, in some mammalian studies; even extending lifespan. has gone one step further, adding calcium to produce LifeAKG™, a patent-pending, highly bioavailable and ultra pure CaAKG supplement, backed by extensive research and double-blind placebo-controlled clinical trials.
Brian Kennedy PhD, who was the Buck Institute’s second CEO, serves as Rejuvant’s Scientific Advisor; he is also a member of the Board. Currently, Dr Kennedy is Professor and Director of the Center for Healthy Aging at the National University of Singapore, and with a plethora of widely-cited papers on aging and longevity under his belt, he is regarded as an expert in the science of gerontology.
Visit Longevity. Technology — https://bit.ly/3PwtH8Y
Follow Longevity. Technology on:
Twitter — https://bit.ly/3AMIXuq.
Facebook — https://bit.ly/3z8H1v5
Instagram — https://bit.ly/3IDvVRX
Linkedin — https://bit.ly/3yIfDmf
Comments are closed.